These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 860164)

  • 1. Levodopa in parkinsonism.
    Slome R
    S Afr Med J; 1977 Mar; 51(11):338-40. PubMed ID: 860164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 3. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S; Chouza C; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):239-54. PubMed ID: 1018727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 5. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 7. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 8. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute stepwise challenge test with levodopa in treated patients with parkinsonism.
    Feng T; Li W; Lu L; Wang Y; Shi W; Zhang J; Wang Y; Chan P
    Parkinsonism Relat Disord; 2009 Jun; 15(5):354-8. PubMed ID: 19010079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H; Siegfried J
    Eur Neurol; 1976; 14(5):321-8. PubMed ID: 949985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The problems of L-dopa therapy in the course of Parkinson syndrome].
    Emskötter T; Lachenmayer L; Heidenreich C
    Fortschr Neurol Psychiatr; 1989 May; 57(5):192-7. PubMed ID: 2737589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP; Bass-Verrey F
    J Neural Transm; 1976; 38(3-4):249-58. PubMed ID: 956811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinsonism in the elderly.
    Hildick-Smith M
    Curr Med Res Opin; 1982; 7(Suppl 1):14-22. PubMed ID: 7105791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dystonia--L-dopa responsive or juvenile parkinsonism?
    Rondot P; Ziegler M
    J Neural Transm Suppl; 1983; 19():273-81. PubMed ID: 6583312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.